PsA bDMARD "ranking" system by systematic literature review looked at 30 RCTs Highest probability of achieving ACR20 and PASI90: infliximab, golimumab and bimekizumab #ACRBest Abs#2123 @RheumNow #ACR22 https://t.co/KpW0p2KAQZ